Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in J Infect

Retrieve available abstracts of 113 articles:
HTML format

Single Articles

    June 2022
  1. XIAO J, Zhu Q, Yang F, Zeng S, et al
    The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China:a longitudinal surveillance study.
    J Infect. 2022 Jun 26. pii: S0163-4453(22)00376.
    PubMed     Abstract available

  2. YIN Y, Li X, Qian C, Cheng B, et al
    Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study.
    J Infect. 2022 Jun 24. pii: S0163-4453(22)00374.

  3. LAZARUS R, Taucher C, Brown C, Corbic I, et al
    Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
    J Infect. 2022 Jun 16. pii: S0163-4453(22)00361.
    PubMed     Abstract available

  4. WORSLEY CM, van der Mescht MA, Hoffman D, Meyer PWA, et al
    Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00360.

  5. KANG SW, Kim JY, Park H, Lim SY, et al
    Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00355.

  6. XU QY, Li QL, Jia ZJ, Wu MJ, et al
    Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study.
    J Infect. 2022 Jun 9. pii: S0163-4453(22)00356.

  7. CHEN CH, Janapatla RP, Su LH, Li HC, et al
    Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: A multi-center clinical microbiological study after PCV13 implementation.
    J Infect. 2022;84:788-794.
    PubMed     Abstract available

  8. PAPAILIOU S, Soldatou A, Marmarinos A, Avgeris M, et al
    Inadequate protection against measles and rubella among pregnant women in Greece during the last measles outbreak.
    J Infect. 2022;84:e95-e97.

    May 2022
  9. NISHIKIMI A, Watanabe K, Watanabe A, Yasuoka M, et al
    Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey.
    J Infect. 2022 May 20. pii: S0163-4453(22)00307.

  10. ZHANG YM, Liu XZ, Lin MM, Zan JC, et al
    Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients.
    J Infect. 2022 May 9. pii: S0163-4453(22)00260.

  11. DIMEGLIO C, Migueres M, Chapuy-Regaud S, Da-Silva I, et al
    Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response.
    J Infect. 2022 May 7. pii: S0163-4453(22)00258.

  12. MARSAY L, Dold C, Paterson GK, Yamaguchi Y, et al
    Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.
    J Infect. 2022;84:658-667.
    PubMed     Abstract available

    April 2022
  13. JIMENEZ D, Martinez-Sanz J, Sainz T, Calvo C, et al
    Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00248.
    PubMed     Abstract available

  14. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Reduced neutralizing antibody response in naive Covishield vaccinees against Omicron emphasizes booster vaccination.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00213.

  15. PANDIT P, Bhatt P, Sahay RR, Joshi Y, et al
    A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00205.

  16. LIU X, Munro APS, Feng S, Janani L, et al
    Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00200.
    PubMed     Abstract available

  17. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Serum C reactive protein predicts humoral response after BNT162b2 booster administration.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00197.

  18. YADAV PD, Sahay RR, Agrawal S, Shete A, et al
    Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00193.

  19. LIU Y, Li P, Yang L, Li P, et al
    High vaccination coverage slows down genetic diversity of SARS-CoV-2.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00191.

  20. CHENG CY, Hsiao SH, Fang TC, Lin YC, et al
    SARS-CoV2 Antibody Response After a Third Dose of Heterologous ChAdOx1 nCoV-19 and Moderna Vaccine in Chronic Dialysis Patients.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00190.

  21. LIN J, Dobbins T, Wood JG, Bernardo C, et al
    Impact of a national immunisation program on herpes zoster incidence in Australia.
    J Infect. 2022;84:537-541.
    PubMed     Abstract available

    March 2022
  22. SCHILDGEN V, Lusebrink J, Schildgen O
    Compulsary SARS-CoV-2 (booster-) vaccination in healthcare facilities can not replace personal protection measures while dealing with vulnarable individuals.
    J Infect. 2022 Mar 23. pii: S0163-4453(22)00173.

  23. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naive vaccinees.
    J Infect. 2022 Mar 19. pii: S0163-4453(22)00170.

  24. DIMEGLIO C, Loubes JM, Migueres M, Saune K, et al
    Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants.
    J Infect. 2022 Mar 17. pii: S0163-4453(22)00140.

  25. XIANG B, Yang L, Ye Z, Ren T, et al
    Vaccination of Susceptible Animals Against SARS-CoV-2.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00131.

  26. FERRE VM, Lebourgeois S, Chenane HR, Menidjel R, et al
    Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00126.

  27. BONNET B, Chabrolles H, Archimbaud C, Brebion A, et al
    Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00132.

  28. GIMENEZ E, Albert E, Burgos JS, Peiro S, et al
    SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00124.
    PubMed     Abstract available

  29. BONGIOVANNI M, Spada E, De Angelis C, Liuzzi G, et al
    SARS-CoV-2: about reinfection, vaccination and neutralizing antibodies.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00125.

  30. SYED MA DR, A/Qotba HA Dr, Al Nuaimi AS Dr
    Effectiveness of COVID-19 vaccines in Qatar.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00121.

  31. SCHALTZ-BUCHHOLZER F, Bjerregard Oland C, Berendsen M, Bjerregaard-Andersen M, et al
    Maternal BCG primes for enhanced health benefits in the newborn.
    J Infect. 2022;84:321-328.
    PubMed     Abstract available

  32. AU WY, Ye C, Briner SL, Suarez GD, et al
    Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00123.

    February 2022
  33. PUTRI DU, Lin CF, Hung CS, Huang CK, et al
    Distinct B and NKT cell Responses Shape the Delayed Response to ChAdOx1 nCoV-19 Vaccine in End-Stage Renal Disease.
    J Infect. 2022 Feb 28. pii: S0163-4453(22)00116.

  34. HAYASHI JY, Simizo A, Miyamoto JG, Costa LVS, et al
    Humoral and Cellular Responses to Vaccination with Homologous CoronaVac or ChAdOx1 and Heterologous Third Dose with BNT162b2.
    J Infect. 2022 Feb 27. pii: S0163-4453(22)00115.

  35. TANG K, Wu X, Luo Y, Wei Z, et al
    Meta-analysis of Immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00081.

  36. SAHAY RR, Patil DY, Sapkal GN, Deshpande GR, et al
    SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00082.

  37. FERRI S, Polidoro A, Ciacciarelli M, Ceratti U, et al
    Decline of immune humoral response after BNT162b2 Vaccine.
    J Infect. 2022 Feb 17. pii: S0163-4453(22)00076.

  38. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Assessment 2 months after the administration of a 3rd dose mRNA: A new variant-adapted vaccine is expected.
    J Infect. 2022 Feb 15. pii: S0163-4453(22)00073.

  39. LIU F, Wang H, Cao Y, Zhang N, et al
    Effectiveness of varicella vaccine in 1-year-old children: a matched case-control study.
    J Infect. 2022 Feb 11. pii: S0163-4453(22)00069.

  40. WESTROP SJ, Whitaker HJ, Powell AA, Power L, et al
    Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
    J Infect. 2022 Feb 4. pii: S0163-4453(22)00055.
    PubMed     Abstract available

  41. ESTOFOLETE CF, Fares GF, Banho CA, Sacchetto L, et al
    Predictors of death in COVID-19 vaccine breakthrough infections in Brazil.
    J Infect. 2022 Feb 2. pii: S0163-4453(22)00059.

    January 2022
  42. XU W, Tang J, Chen C, Wang C, et al
    Safety and Efficacy of the Covid-19 Vaccine in children andor adolescents: A meta-analysis.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00050.

  43. MATTIUZZI C, Lippi G
    COVID-19 vaccines efficacy in preventing or limiting SARS-CoV-2 infections.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00051.

  44. MENSAH AA, Lacy J, Stowe J, Seghezzo G, et al
    Evaluation of disease severity during SARS-COV-2 reinfection, January 2020 to April 2021, England: an observational study.
    J Infect. 2022 Jan 24. pii: S0163-4453(22)00010.
    PubMed     Abstract available

  45. DUCLOUX D, Bamoulid J, Chabannes M, Colladant M, et al
    Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients.
    J Infect. 2022 Jan 21. pii: S0163-4453(22)00020.

  46. FAUSTINI S, Shields A, Banham G, Wall N, et al
    Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00002.

  47. YANG Y, Gong X, Yang L, Li J, et al
    Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00005.

  48. DE MICHELENA P, Torres I, Albert E, Bracho A, et al
    Impact of time elapsed since full vaccination on SARS-CoV-2 RNA load in Delta-variant breakthrough COVID-19.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00007.

  49. WHITAKER HJ, Tsang RS, Byford R, Andrews NJ, et al
    Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups.
    J Infect. 2022 Jan 3. pii: S0163-4453(21)00664.
    PubMed     Abstract available

  50. MARRAMS ARM, Kobayashi T, Suzuki H, Alsuhaibani M, et al
    Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis.
    J Infect. 2022 Jan 1. pii: S0163-4453(21)00658.
    PubMed     Abstract available

    December 2021
  51. MIN JY, Mwakingwe-Omari A, Riley M, Molo LY, et al
    The Adjuvanted Recombinant Zoster Vaccine Co-Administered with the 13-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=50 Years: a Randomized Trial.
    J Infect. 2021 Dec 25. pii: S0163-4453(21)00651.
    PubMed     Abstract available

  52. COSTA R, Olea B, Bracho MA, Albert E, et al
    RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00641.

  53. MANOLACHE NG, Ursachi V, Scohy A, Desmet C, et al
    Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases.
    J Infect. 2021 Dec 14. pii: S0163-4453(21)00597.

  54. MAK WA, Koeleman JGM, van der Vliet M, Keuren F, et al
    SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.
    J Infect. 2021 Dec 9. pii: S0163-4453(21)00593.
    PubMed     Abstract available

    November 2021
  55. OESER C, Whitaker H, Linley E, Borrow R, et al
    Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.
    J Infect. 2021 Nov 30. pii: S0163-4453(21)00584.

  56. LUCIDARME J, Bai X, Lekshmi A, Clark SA, et al
    Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - first real-world data: Meningococcal B following 4CMenB.
    J Infect. 2021 Nov 25. pii: S0163-4453(21)00579.
    PubMed     Abstract available

  57. ALDERSON MR, Arkwright PD, Bai X, Black S, et al
    Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review.
    J Infect. 2021 Nov 24. pii: S0163-4453(21)00578.
    PubMed     Abstract available

  58. LEBOURGEOIS S, Menidjel R, Chenane HR, Ferre VM, et al
    Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
    J Infect. 2021 Nov 19. pii: S0163-4453(21)00556.

  59. GIMENEZ E, Alberola J, Torres I, Albert E, et al
    Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2021 Nov 2. pii: S0163-4453(21)00542.

    October 2021
  60. CHONG Y, Tani N, Goto T, Yonekawa A, et al
    Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents.
    J Infect. 2021 Oct 20. pii: S0163-4453(21)00508.

  61. GUPTA A, Bhoyar RC, Mirza S, Jolly B, et al
    SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker.
    J Infect. 2021 Oct 19. pii: S0163-4453(21)00506.

  62. ANIS E, Haas EJ, Indenbaum V, Singer SR, et al
    A prolonged, nationwide measles outbreak despite very high vaccination coverage in Israel, 2018-19.
    J Infect. 2021 Oct 6. pii: S0163-4453(21)00497.
    PubMed     Abstract available

    September 2021
  63. FERRE VM, Lebourgeois S, Menidjel R, Collin G, et al
    Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
    J Infect. 2021 Sep 29. pii: S0163-4453(21)00488.

  64. LUNA-MUSCHI A, Borges IC, de Faria E, Barboza AS, et al
    Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: a prospective cohort study of vaccinated and unvaccinated healthcare workers.
    J Infect. 2021 Sep 16. pii: S0163-4453(21)00474.

    August 2021
  65. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected.
    J Infect. 2021 Aug 23. pii: S0163-4453(21)00433.
    PubMed     Abstract available

  66. WEISSMAN YL, Cooper L, Sternbach N, Ashkenazi-Hoffnung L, et al
    Clinical efficacy and safety of high dose trivalent influenza vaccine in adults and immunosuppressed populations -a systematic review and meta-analysis.
    J Infect. 2021 Aug 20. pii: S0163-4453(21)00417.
    PubMed     Abstract available

  67. GODOY P, Garcia-Cenoz M, Rius C, Munoz-Almagro C, et al
    Effectiveness of maternal pertussis vaccination in protecting newborn: a matched case-control study: Maternal pertussis vaccination in protecting newborn.
    J Infect. 2021 Aug 15. pii: S0163-4453(21)00404.
    PubMed     Abstract available

  68. DOUXFILS J, Gillot C, Mullier F, Favresse J, et al
    Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ.
    J Infect. 2021 Aug 15. pii: S0163-4453(21)00405.

  69. ALLEN N, Brady M, Martin AIC, Domegan L, et al
    Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals.
    J Infect. 2021 Aug 9. pii: S0163-4453(21)00394.

  70. YAHI N, Chahinian H, Fantini J
    Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination ?
    J Infect. 2021 Aug 9. pii: S0163-4453(21)00392.
    PubMed     Abstract available

  71. Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00388.

  72. GOBBI F, Buonfrate D, Silva R, Martini D, et al
    Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine: SARS-CoV-2 infection early after the first vaccine dose.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00390.

  73. Predominance of Delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021.
    J Infect. 2021 Aug 5. pii: S0163-4453(21)00387.

  74. UDDEN F, Runow E, Slotved HC, Fuursted K, et al
    Characterization of Streptococcus pneumoniae detected in clinical respiratory tract samples in southern Sweden 2 to 4 years after introduction of PCV13.
    J Infect. 2021;83:190-196.
    PubMed     Abstract available

    July 2021
  75. WANG H, Liu F, Cao Y, Zhang N, et al
    Epidemiological characteristics of Varicella before and after the implementation of two-dose vaccination schedule in Chaoyang District, Beijing, 2007-2019.
    J Infect. 2021 Jul 29. pii: S0163-4453(21)00378.

  76. BENE MC, Bittencourt MC, Chevallier P
    Post-SARS-CoV-2 vaccination specific antibody decrease : let's get the half-full glass perspective.
    J Infect. 2021 Jul 28. pii: S0163-4453(21)00370.

  77. EBANKS D, Faustini S, Shields A, Parry H, et al
    Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays.
    J Infect. 2021 Jul 26. pii: S0163-4453(21)00363.

  78. GIDARI A, Sabbatini S, Bastianelli S, Pierucci S, et al
    Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
    J Infect. 2021 Jul 25. pii: S0163-4453(21)00362.
    PubMed     Abstract available

    Crossing the Rubicon: a Fine Line between Waiting and Vaccinating Adolescents against COVID-19.
    J Infect. 2021 Jul 21. pii: S0163-4453(21)00357.
    PubMed     Abstract available

  80. MOMBELLI M, Hoschler K, Cavassini M, Pascual M, et al
    Seasonal Trivalent Inactivated Influenza Vaccine with Topical Imiquimod in Immunocompromised Patients: a Randomized Controlled Trial.
    J Infect. 2021 Jul 20. pii: S0163-4453(21)00353.
    PubMed     Abstract available

  81. ANGELETTI S, Giovanetti M, Fogolari M, De Florio L, et al
    Detection of a SARS-CoV-2 P.1.1 variant lacking N501Y in a vaccinated Health Care worker in Italy.
    J Infect. 2021 Jul 5. pii: S0163-4453(21)00325.
    PubMed     Abstract available

  82. FAVRESSE J, Douxfils J
    Importance of Sample Dilution in the Evaluation of the Antibody Response after SARS-CoV-2 Vaccination.
    J Infect. 2021 Jul 4. pii: S0163-4453(21)00327.

    June 2021
  83. HSU L, Wisplinghoff H, Kossow A, Hurrass J, et al
    Limited protection against SARS-CoV-2 infection and virus transmission after mRNA vaccination.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00320.

  84. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00321.

  85. TRE-HARDY M, Cupaiolo R, Wilmet A, Beukinga I, et al
    Waning antibodies in SARS-CoV-2 naive vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.
    J Infect. 2021 Jun 20. pii: S0163-4453(21)00314.

  86. DIMEGLIO C, Herin F, Miedouge M, Da-Silva I, et al
    One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection.
    J Infect. 2021 Jun 17. pii: S0163-4453(21)00312.

  87. KWOK KO, McNeil EB, Tsoi MTF, Wei VWI, et al
    Will achieving herd immunity be a road to success to end the COVID-19 pandemic?
    J Infect. 2021 Jun 9. pii: S0163-4453(21)00287.
    PubMed     Abstract available

  88. AKPOLAT T, Uzun O
    J Infect. 2021 Jun 8. pii: S0163-4453(21)00285.

    May 2021
  89. RAW RK, Kelly C, Rees J, Wroe C, et al
    Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination.
    J Infect. 2021 May 29. pii: S0163-4453(21)00277.

  90. PEZZATI L, Giacomelli A, Mileto D, Conti F, et al
    Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: a cross-sectional study.: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine.
    J Infect. 2021 May 29. pii: S0163-4453(21)00271.

  91. BUTT AA, Khan T, Yan P, Shaikh OS, et al
    Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination.
    J Infect. 2021 May 28. pii: S0163-4453(21)00263.

  92. J BP, Jolly B, John N, Bhoyar RC, et al
    Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India.
    J Infect. 2021 May 24. pii: S0163-4453(21)00260.

  93. WHITAKER HJ, Elgohari S, Rowe C, Otter AD, et al
    Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021.
    J Infect. 2021 May 11. pii: S0163-4453(21)00224.
    PubMed     Abstract available

  94. SANSONE E, Tiraboschi M, Sala E, Albini E, et al
    Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.
    J Infect. 2021 May 6. pii: S0163-4453(21)00225.
    PubMed     Abstract available

    April 2021
  95. GARVEY MI, Wilkinson MAC, Holden E, Shields A, et al
    Early observations on the impact of a healthcare worker COVID-19 vaccination programme at a major UK tertiary centre.
    J Infect. 2021 Apr 29. pii: S0163-4453(21)00214.

  96. MARTINON-TORRES F, Banzhoff A, Azzari C, De Wals P, et al
    Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination: Real-world effectiveness of MenB vaccination.
    J Infect. 2021 Apr 29. pii: S0163-4453(21)00218.
    PubMed     Abstract available

  97. DONADIO C, Rainone A, Gouronnec A, Belmin J, et al
    Asymptomatic COVID-19 cases among older patients despite BNT162b2 vaccination: a case series in a geriatric rehabilitation ward during an outbreak.
    J Infect. 2021 Apr 11. pii: S0163-4453(21)00167.

  98. LODI L, Moriondo M, Nieddu F, Ricci S, et al
    Molecular typing of group B Neisseria meningitidis'subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period
    J Infect. 2021;82:28-36.
    PubMed     Abstract available

    February 2021
  99. ABAD R, Garcia-Amil C, Navarro C, Martin E, et al
    Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: evolution of the vaccine antigen factor H binding protein (FHbp).
    J Infect. 2021 Feb 18. pii: S0163-4453(21)00087.
    PubMed     Abstract available

  100. BAO HL, Jin C, Wang S, Song Y, et al
    Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: A nationwide population-based study.
    J Infect. 2021 Feb 18. pii: S0163-4453(21)00084.
    PubMed     Abstract available

  101. ANTONELLI M, Capdevila J, Chaudhari A, Granerod J, et al
    Optimal symptom combinations to aid COVID-19 case identification: analysis from a community-based, prospective, observational cohort.
    J Infect. 2021 Feb 13. pii: S0163-4453(21)00079.
    PubMed     Abstract available

    December 2020
  102. ZENG H, Yi L, Chen X, Zhou H, et al
    First detection of EV-A71 genotype C1 in China Emergence of a non vaccine-cognate enterovirus A71 genotype C1 in mainland China.
    J Infect. 2020 Dec 26. pii: S0163-4453(20)30782.
    PubMed     Abstract available

    November 2020
  103. LEVI M, Miglietta A, Romeo G, Bartolacci S, et al
    Letter in response to article in Journal of Infection: Impact of Routine Infant BCG Vaccination on COVID-19.
    J Infect. 2020 Nov 25. pii: S0163-4453(20)30718.

  104. HAMED E, Alnuaimi AS, Syed MA, Elhamid MA, et al
    Clinical characteristics of 51815 patients presenting with positive and negative SARS-CoV-2 swab results in primary health care settings.
    J Infect. 2020 Nov 13. pii: S0163-4453(20)30709.

  105. AYE AMM, Bai X, Borrow R, Bory S, et al
    Meningococcal disease surveillance in the Asia-Pacific region (2020): The global meningococcal initiative.
    J Infect. 2020;81:698-711.
    PubMed     Abstract available

    October 2020
  106. SUAYA JA, Mendes RE, Sings HL, Arguedas A, et al
    Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 20092017.
    J Infect. 2020;81:557-566.
    PubMed     Abstract available

  107. SMITH EL, Wheeler I, Adler H, Ferreira DM, et al
    Upper airways colonisation of Streptococcus pneumoniae in adults aged 60 years and older: A systematic review of prevalence and individual participant data meta-analysis of risk factors.
    J Infect. 2020;81:540-548.
    PubMed     Abstract available

    August 2020
  108. GLATMAN-FREEDMAN A, Kaufman Z, Applbaum Y, Dichtiar R, et al
    Respiratory Syncytial Virus hospitalization burden: a nation-wide population-based analysis, 2000-2017.
    J Infect. 2020;81:297-303.
    PubMed     Abstract available

  109. GOMEZ-RIAL J, Rivero-Calle I, Salas A, Martinon-Torres F, et al
    Rotavirus and autoimmunity.
    J Infect. 2020;81:183-189.
    PubMed     Abstract available

    July 2020
  110. NYAZIKA TK, Law A, Swarthout TD, Sibale L, et al
    Influenza-like illness is associated with high pneumococcal carriage density in Malawian children.
    J Infect. 2020 Jul 22. pii: S0163-4453(20)30495.
    PubMed     Abstract available

    May 2020
  111. DEGHMANE AE, Haeghebaert S, Hong E, Jousset A, et al
    Emergence of new genetic lineage, ST-9316, of Neisseria meningitidis group W in Hauts-de-France region, France 2013-2018.
    J Infect. 2020;80:519-526.
    PubMed     Abstract available

    March 2020
  112. BEEBEEJAUN K, Parikh SR, Campbell H, Gray S, et al
    Invasive meningococcal disease: Timing and cause of death in England, 2008-2015.
    J Infect. 2020;80:286-290.
    PubMed     Abstract available

    February 2020
  113. CAMPBELL H, Andrews N, Parikh S, Ribeiro S, et al
    Variable clinical presentation by the main capsular groups causing invasive meningococcal disease in England.
    J Infect. 2020;80:182-189.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.